Sponsored Projects Administration

The industry’s spotlight on cancer immunotherapies

Published October 28, 2013 by OSP


Over the past year the excitement in biopharma R&D circles about the therapeutic punch of cancer immunotherapies has reached fever pitch, and the intense R&D focus hasn't escaped the notice of top analysts who are making some megablockbuster projections on the commercial impact these new drugs are likely to have. Read more: Analysts offer giddy forecasts for booming cancer immunotherapy pipeline.

Read More>